Cargando…
Cross resistance to diverse anticancer nicotinamide phosphoribosyltransferase inhibitors induced by FK866 treatment
Cross-resistance to drugs remains an unsolved problem in cancer chemotherapy. This study elucidates a molecular mechanism of cross-resistance to diverse inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) with anticancer activity. We generated a variant of the human colon cancer cell line H...
Autores principales: | Ogino, Yoko, Sato, Akira, Uchiumi, Fumiaki, Tanuma, Sei-ichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5893253/ https://www.ncbi.nlm.nih.gov/pubmed/29662658 http://dx.doi.org/10.18632/oncotarget.24731 |
Ejemplares similares
-
Structural Basis of Beneficial Design for Effective Nicotinamide Phosphoribosyltransferase Inhibitors
por: Tanuma, Sei-ichi, et al.
Publicado: (2020) -
A Nicotinamide Phosphoribosyltransferase Inhibitor, FK866, Suppresses the Growth of Anaplastic Meningiomas and Inhibits Immune Checkpoint Expression by Regulating STAT1
por: Deng, Yuxuan, et al.
Publicado: (2022) -
Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies
por: Biniecka, Paulina, et al.
Publicado: (2023) -
The NAMPT inhibitor FK866 reverts the damage in spinal cord injury
por: Esposito, Emanuela, et al.
Publicado: (2012) -
[18F]FLT and [18F]FDG PET for Non-invasive Treatment Monitoring of the Nicotinamide Phosphoribosyltransferase Inhibitor APO866 in Human Xenografts
por: Munk Jensen, Mette, et al.
Publicado: (2013)